Condition
Diffuse Instrinsic Ponitine Glioma
Total Trials
1
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
1 treatments under study, led by Nimotuzumab
Research Leaders
13 sponsors active, led by Dr. von Haunersches Children's Medical Hospital, University of Munich, Germany
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
Trial Status
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (1)
Showing 1 of 1 trials
Showing all 1 trials
Research Network
Common Treatments
- Nimotuzumab1
Active Sponsors
- Dr. von Haunersches Children's Medical Hospital, University of Munich, Germany1
- Children's Medical Hospital, University of Homburg/Saar, Homburg/Saar, Germany1
- Heinrich-Heine University, Duesseldorf1
- Istituto Nazinonale Tumori, Div. of Paediatric Oncology,Milano, Italy1
- University of Wuerzburg1
Top Investigators
University of Bonn